Iizuka Norio, Sakaida Isao, Moribe Toyoki, Fujita Nozomi, Miura Toshiaki, Stark Markus, Tamatsukuri Shigeru, Ishitsuka Hideo, Uchida Koichi, Terai Shuji, Sakamoto Kazuhiko, Tamesa Takao, Oka Masaaki
Department of Surgery II, Yamaguchi University Postgraduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi 755-8505.
Anticancer Res. 2006 Nov-Dec;26(6C):4713-9.
Circulating cell-free DNA is present in increased amounts in the blood of patients with one of several forms of cancer.
A real-time PCR assay with glutathione S-transferase pi (GSTP1) gene was used to measure cell-free DNA levels in the sera of 52 patients with hepatocellular carcinoma (HCC) associated with hepatitis C virus (HCV), which included 30 HCV carriers without known HCC and 16 HCV-negative non-cancer patients (controls).
Cell-free DNA levels were significantly higher in the sera from HCC patients than in the sera from HCV carriers or the control subjects. Cell-free DNA levels were associated with the degree of tumor differentiation and size but not patient age, gender, TNM stage or levels of alpha-fetoprotein (AFP) or protein induced by vitamin K absence (PIVKA-II). The cell-free DNA assay had a sensitivity of 69.2% and a specificity of 93.3% in discriminating HCC and HCV carriers at the optimal cut-off value of 73.0 ng/ml, with an area of 0.90 (95% CI, 0.83-0.96) under the receiver operating characteristic curve. The discriminative power of cell-free DNA was superior to that of AFP or PIVKA-II.
Our results showed that levels of circulating cell-free DNA are significantly increased in sera of patients with HCV-associated HCC, suggesting that circulating cell-free DNA may be a good biomarker specific for HCV-associated HCC.
在患有几种癌症之一的患者血液中，循环游离DNA的含量会增加。
采用谷胱甘肽S-转移酶pi（GSTP1）基因的实时聚合酶链反应（PCR）检测法，测量52例丙型肝炎病毒（HCV）相关肝细胞癌（HCC）患者血清中的游离DNA水平，其中包括30例无已知HCC的HCV携带者和16例HCV阴性的非癌症患者（对照组）。
HCC患者血清中的游离DNA水平显著高于HCV携带者或对照组受试者血清中的游离DNA水平。游离DNA水平与肿瘤分化程度和大小相关，但与患者年龄、性别、TNM分期或甲胎蛋白（AFP）或维生素K缺乏诱导蛋白（PIVKA-II）水平无关。在最佳临界值为73.0 ng/ml时，游离DNA检测在区分HCC和HCV携带者方面的灵敏度为69.2%，特异性为93.3%，在受试者工作特征曲线下的面积为0.90（95%可信区间，0.83 - 0.96）。游离DNA的鉴别能力优于AFP或PIVKA-II。
我们的结果表明，HCV相关HCC患者血清中循环游离DNA水平显著升高，提示循环游离DNA可能是HCV相关HCC的一种良好的特异性生物标志物。
